28 related articles for article (PubMed ID: 1943746)
1. Y It Matters-Sex Differences in Fetal Lung Development.
Laube M; Thome UH
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327629
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
[TBL] [Abstract][Full Text] [Related]
3. Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive.
Maggard MA; Catlin EA; Hudson PL; Donahoe PK; MacLaughlin DT
Metabolism; 1996 Feb; 45(2):190-5. PubMed ID: 8596488
[TBL] [Abstract][Full Text] [Related]
4. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase.
Cigarroa FG; Coughlin JP; Donahoe PK; White MF; Uitvlugt N; MacLaughlin DT
Growth Factors; 1989; 1(2):179-91. PubMed ID: 2560399
[TBL] [Abstract][Full Text] [Related]
6. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
[TBL] [Abstract][Full Text] [Related]
7. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
8. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
9. Müllerian inhibiting substance in reproduction and cancer.
Donahoe PK
Mol Reprod Dev; 1992 Jun; 32(2):168-72. PubMed ID: 1637555
[TBL] [Abstract][Full Text] [Related]
10. Mullerian inhibiting substance: a fetal hormone with surgical implications.
Hutson JM; Donahoe PK; Budzik GP
Aust N Z J Surg; 1985 Dec; 55(6):599-605. PubMed ID: 2870703
[TBL] [Abstract][Full Text] [Related]
11. A possible purification of mullerian inhibiting substance and a model for its mechanism of action.
Budzik GP; Donahoe PK; Hutson JM
Prog Clin Biol Res; 1985; 171():207-23. PubMed ID: 2984697
[No Abstract] [Full Text] [Related]
12. Müllerian inhibiting substance: new perspectives and future directions.
Catlin EA; MacLaughlin DT; Donahoe PK
Microsc Res Tech; 1993 Jun; 25(2):121-33. PubMed ID: 8518480
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
